Krebs Biochemicals & Industries Limited
NSE:KREBSBIO.NS
84.37 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 504.215 | 521.344 | 529.406 | 386.064 | 235.838 | 371.327 | 254.092 | 32.554 | 1.585 | 0.112 | 138.697 | 707.6 | 724.446 | 462.338 | 455.521 | 506.946 |
| Cost of Revenue
| 298.277 | 256.775 | 737 | 522.323 | 329.107 | 388.996 | 259.11 | 26.911 | 46.37 | 9.081 | 140.093 | 405.427 | 579.55 | 304.979 | 340.041 | 310.422 |
| Gross Profit
| 205.938 | 264.569 | -207.594 | -136.259 | -93.269 | -17.669 | -5.018 | 5.643 | -44.785 | -8.969 | -1.396 | 302.173 | 144.896 | 157.36 | 115.48 | 196.524 |
| Gross Profit Ratio
| 0.408 | 0.507 | -0.392 | -0.353 | -0.395 | -0.048 | -0.02 | 0.173 | -28.256 | -80.08 | -0.01 | 0.427 | 0.2 | 0.34 | 0.254 | 0.388 |
| Reseach & Development Expenses
| 12.69 | 11.259 | 16.381 | 14.658 | 9.694 | 9.548 | 13.765 | 0.553 | 2.245 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 8.598 | 11.153 | 6.715 | 8.413 | 11.76 | 9.113 | 0.81 | 0.605 | 0 | 17.293 | 244.932 | 60.426 | 70.401 | 34.838 | 43.075 |
| Selling & Marketing Expenses
| 0 | 0 | 0.038 | 0.047 | 0.976 | 0.202 | 0.227 | 0.06 | 0 | 0 | 1.456 | 4.442 | 0 | 0 | 0 | 0 |
| SG&A
| 360.841 | 8.598 | 11.191 | 32.867 | 9.389 | 11.962 | 9.34 | 0.87 | 0.605 | 10.16 | 95.482 | 249.374 | 60.426 | 70.401 | 34.838 | 43.075 |
| Other Expenses
| 4.513 | 6.201 | 10.169 | 6.213 | 10.169 | 10.169 | 11.094 | 126.43 | 7.877 | 0 | 0 | 162.868 | 109.288 | 165.023 | 102.836 | 168.339 |
| Operating Expenses
| 360.841 | 487.958 | 195.139 | 90.75 | 146.994 | 131.435 | 120.726 | 127.3 | 121.56 | 6.737 | 127.812 | 412.242 | 169.713 | 235.423 | 137.674 | 211.414 |
| Operating Income
| -154.903 | -217.187 | -402.916 | -227.009 | -240.263 | -149.104 | -114.291 | -160.493 | -163.204 | -46.866 | -128.905 | -193.396 | -98.904 | -146.804 | -435.384 | -114.676 |
| Operating Income Ratio
| -0.307 | -0.417 | -0.761 | -0.588 | -1.019 | -0.402 | -0.45 | -4.93 | -102.968 | -418.446 | -0.929 | -0.273 | -0.137 | -0.318 | -0.956 | -0.226 |
| Total Other Income Expenses Net
| -42.381 | -29.732 | -42.352 | -56.577 | -48.457 | -51.011 | -63.958 | -38.836 | 5.44 | -9.118 | 16.901 | -83.328 | -74.087 | -104.171 | -413.19 | -99.786 |
| Income Before Tax
| -197.284 | -246.919 | -445.268 | -283.586 | -288.72 | -200.115 | -178.249 | -160.493 | -163.204 | -55.984 | -112.004 | -193.397 | -98.904 | -146.804 | -435.385 | -114.676 |
| Income Before Tax Ratio
| -0.391 | -0.474 | -0.841 | -0.735 | -1.224 | -0.539 | -0.702 | -4.93 | -102.968 | -499.857 | -0.808 | -0.273 | -0.137 | -0.318 | -0.956 | -0.226 |
| Income Tax Expense
| 67.495 | 65.357 | 13.872 | 6.213 | 12.727 | 10.725 | 12.349 | 4.024 | -2.652 | 3.999 | 7.402 | -19.016 | -32.081 | -90.125 | -8.959 | -12.781 |
| Net Income
| -197.284 | -246.919 | -445.268 | -283.586 | -288.72 | -200.115 | -178.249 | -160.493 | -163.204 | -59.983 | -104.602 | -174.381 | -66.823 | -56.679 | -426.426 | -101.895 |
| Net Income Ratio
| -0.391 | -0.474 | -0.841 | -0.735 | -1.224 | -0.539 | -0.702 | -4.93 | -102.968 | -535.563 | -0.754 | -0.246 | -0.092 | -0.123 | -0.936 | -0.201 |
| EPS
| -9.16 | -11.45 | -20.65 | -14.45 | -16.04 | -12.03 | -12.97 | -11.28 | -12.06 | -4.7 | -11 | -17.7 | -7.13 | -6.05 | -50.76 | -13.95 |
| EPS Diluted
| -9.16 | -11.45 | -20.65 | -14.45 | -16.04 | -12.03 | -12.97 | -11.28 | -12.06 | -4.7 | -11 | -17.7 | -7.13 | -6.05 | -50.76 | -13.95 |
| EBITDA
| -87.24 | -151.602 | -326.084 | -169.556 | -180.746 | -94.356 | -72.794 | -79.278 | -113.677 | -9.44 | -62.694 | -13.498 | 71.155 | 20.724 | 73.215 | 92.538 |
| EBITDA Ratio
| -0.173 | -0.291 | -0.616 | -0.439 | -0.766 | -0.254 | -0.286 | -2.435 | -71.721 | -84.286 | -0.452 | -0.019 | 0.098 | 0.045 | 0.161 | 0.183 |